[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521231":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":32,"responsibleParty":48,"collaborators":51,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Guangdong Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"chidamide and azacitidine","EXPERIMENTAL",null,[13],"Drug: chidamide and azacitidine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.\n\nazacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.",[9],[20],{"name":21,"affiliation":22,"role":23},"WENG jian yu, M.D.","Department of Hematology, Guangdong Provincial People's Hospital","PRINCIPAL_INVESTIGATOR",[25,29],{"name":21,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","020-83827812","wengjianyu1969@163.com",{"name":30,"role":26,"phone":27,"phoneExt":11,"email":31},"Ling Wei, M.D.","nick97@163.com",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":11,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Guangzhou","Guangdong","China",{"type":39,"coordinates":40},"Point",[41,42],113.25,23.11667,{"lat":42,"lon":41},[45],{"name":21,"role":26,"phone":46,"phoneExt":11,"email":47},"（020）83827812","wsswjy@sina.com",{"type":23,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"WENG Jian yu","professor",[52],{"name":53,"class":54},"Chipscreen Biosciences, Ltd.","INDUSTRY","100521231",false,"NCT06066905","A Study of Chidamide With AZA in MRD Positive AML After Transplant","Inclusion Criteria:\n\n1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);\n2. ≥18 years old;\n3. ECOG≤3;\n4. lifespan≥3 months;\n5. Take contraceptive measures;\n6. Sign informed consent.\n\nExclusion Criteria:\n\n1. Allergic to the study drug;\n2. A gastrointestinal condition that prevents oral medication;\n3. active infection;\n4. Dysfunction of vital organs;\n5. other malignancies;\n6. HIV infection;\n7. HBV or HCV;\n8. The QT interval is prolonged;\n9. Pregnant or lactating women;\n10. Is participating in other clinical studies;\n11. The researchers did not consider it appropriate to participate in this study.","ALL","18 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"NA","acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.",[70,71],"AML, Adult","Minimal Residual Disease","2023-10-26",{"date":74,"type":75},"2023-10-27","ACTUAL",{"date":72,"type":64},{"date":78,"type":64},"2026-12",{"name":5,"class":6},1]